A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

BACKGROUND: Checkpoint inhibitors can induce profound anticancer responses, but programmed cell death protein-1 (PD-1) inhibition monotherapy has shown minimal activity in prostate cancer. A published report showed that men with prostate cancer who were resistant to the second-generation androgen re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Graff, Julie N, Beer, Tomasz M, Alumkal, Joshi J, Slottke, Rachel E, Redmond, William L, Thomas, George V, Thompson, Reid F, Wood, Mary A, Koguchi, Yoshinobu, Chen, Yiyi, Latour, Emile, Bergan, Raymond C, Drake, Charles G, Moran, Amy E
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7333874/
https://ncbi.nlm.nih.gov/pubmed/32616555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000642
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados